Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 1.00 |
| ▸ | MAOA | P21397 | 5/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.73 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.66 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.66 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160837 | 1.00 | MAOB (1.00) | MAOBMAOACYP1B1BCHETNFRSF1A | |
| SCHEMBL3049957 | 1.00 | MAOB (1.00) | MAOBMAOACYP1B1BCHETNFRSF1A | |
| SCHEMBL6733854 | 0.92 | MAOB (0.85) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL6733848 | 0.92 | MAOB (0.85) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL9136940 | 0.86 | MAOB (0.80) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL8977012 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL8977005 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL9136943 | 0.86 | MAOB (0.80) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL8965786 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEHSPD1 | |
| SCHEMBL8965792 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | NAGASAKI UNIVERSITY (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2030635-A1 | COMPOSITION FOR DIAGNOSING AMYLOID-RELATED DISEASE | Nagasaki University (JP) | 2009-03-04 | — | — | EP | disclosed |
| EP-1339694-B1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | SYNTEX (U.S.A.) LLC | 2002-07-11 | — | — | US | disclosed |
| US-6417186-B1 | TREATING PAIN, URINARY TRACT INFECTIONS, INFLAMMATION, RESPIRATORY DISEASE STATES FROM ALLERGIES OR ASTHMA, EDEMA FORMATION OR HYPOTENSIVE VASCULAR DISEASES. | SYNTEX (U.S.A.) LLC | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | PTGER1, FFAR1, BDKRB1 | MAOB 3314/4885MAOA 3617/4885CYP1B1 868/4885 |
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | APP, FABP7, APBA1 | MAOB 1093/4885MAOA 1220/4885CYP1B1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.